Medication-overuse headache Medical Services in China

Medication Overuse Headache (MOH) is a secondary headache disorder defined by the International Classification of Headache Disorders (ICHD-3) as headache occurring on ≥15 days per month in patients with pre-existing primary headache (e.g., migraine or tension-type headache), developing as a consequence of regular overuse of acute headache medications for >3 months. Common culprits include triptans, ergotamines, opioids, combination analgesics, and simple analgesics—used on ≥10 or ≥15 days/month depending on drug class. MOH perpetuates a vicious cycle: escalating medication use paradoxically worsens headache frequency and intensity, impairs responsiveness to preventive therapies, and diminishes quality of life. Diagnosis requires meticulous medication history, headache diary analysis, and exclusion of secondary causes via neuroimaging when indicated. First-line management centers on complete withdrawal of overused agents—often requiring supervised inpatient or outpatient detoxification—followed by initiation of evidence-based prophylactic treatment (e.g., topiramate, amitriptyline, CGRP monoclonal antibodies) and non-pharmacologic strategies including cognitive behavioral therapy and lifestyle modification.

China offers distinct advantages for MOH management: its leading neurology centers—such as Beijing Tiantan Hospital and Shanghai Huashan Hospital—host multidisciplinary headache units staffed by IHS-certified specialists with extensive experience in complex MOH withdrawal protocols and long-term relapse prevention. Advanced neuroimaging (3T MRI, quantitative EEG, functional near-infrared spectroscopy) supports precise phenotyping and treatment personalization. Published cohort studies report ≥75% sustained remission at 12 months post-withdrawal in rigorously managed cases. Treatment costs—including diagnostics, inpatient detox, and 3-month follow-up—are typically 40–60% lower than in the US or Western Europe, without compromising clinical standards. As a dedicated medical tourism agency, we facilitate seamless access for international patients: verifying hospital accreditation, coordinating appointments with MOH-specialized neurologists, providing itemized, transparent pricing in advance, arranging visa support and local logistics, and offering bilingual care coordination throughout the diagnostic, therapeutic, and rehabilitation phases.

Treatment Options & Itemized Cost Breakdown: Medication-Overuse Headache (MOH)

Non-Surgical / Conservative Management

*Target Criteria:* Confirmed MOH diagnosis (ICHD-3 criteria), ≥15 headache days/month, regular overuse of acute medications (>10 days/month for triptans/ergots/opioids or >15 days/month for NSAIDs/paracetamol) for ≥3 months.

• •Detoxification & Withdrawal Protocol (Outpatient)

- Cognitive Behavioral Therapy (CBT) sessions (6 sessions, 45 min each): $240–$360 - Preventive medication initiation (e.g., topiramate 50 mg/day × 3 months): $45–$75 - EEG (if atypical features or seizure concern): $60 - Serum liver/kidney function panel (baseline + 2 repeats): $45

• •Structured Inpatient Detox (7–14 days, Grade 3A neurology ward)

- IV hydration + antiemetics + short-term bridging (e.g., prednisone taper): $180–$270 - Daily nursing + vital monitoring: $210–$350 - Discharge summary + 3-month outpatient CBT referral: $30

Surgical / Procedural / Interventional Options

*Eligibility Criteria:* Refractory MOH (>12 months duration, failed ≥2 inpatient detox attempts, no contraindications to anesthesia, confirmed absence of secondary headache etiology on MRI/MRA). *No surgical intervention is standard or evidence-based for MOH.* All listed procedures are off-label, unproven, and not recommended per Chinese Neurological Society guidelines.

• •OnabotulinumtoxinA Injection (off-label use)

- Injection session (31-site paradigm, certified neurologist): $420–$560 - Repeat every 12 weeks × 2 cycles (required for trial): $840–$1,120

• •Sphenopalatine Ganglion (SPG) Block (ultrasound-guided, research setting only)

- SPG block (local anesthetic + corticosteroid, bilateral): $320–$400 - *Note: Not reimbursed; performed only in clinical trials at select 3A centers.*

Special / Complex Condition Management

• •MOH with Comorbid Major Depressive Disorder or Anxiety Disorder

- Integrated neuro-psychiatry care (monthly joint visits): $180–$240/month

• •MOH in Elderly (>75 years) with Polypharmacy

- Home-based nurse follow-up (4 visits): $120

Quick Selection Guide

• •Young Adult (<45), Mild-Moderate MOH, Budget-Conscious: Outpatient detox + CBT ($405–$615 total) — highest evidence, lowest cost.
• •Middle-Aged (45–65), Severe MOH (>20 days/month), Prior Failed Outpatient: Inpatient detox ($1,500–$2,500) — reduces relapse risk by 40% vs outpatient.
• •Elderly with Depression & Polypharmacy: Geriatric assessment + integrated psychiatry ($270–$390 initial) — avoids drug interactions, prioritizes safety.
• •Refractory MOH (>3 failed detoxes): OnabotulinumtoxinA trial ($1,080–$1,360 for 2 cycles) — only after documented failure and multidisciplinary consensus.